Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
GXAI
Gaxos.ai
Sponsored
content by Gaxos.ai
JO
Jolt_Communications
Community Contributor
Gaxos.ai: Early-Stage AI Innovator in Gaming & Health
Key Takeaways Dual AI focus – Gaxos.ai builds AI-powered tools for game developers (via Unity integrations) and AI-driven health services under its RNK Health brand. First signs of commercial traction – After years of development, the company reported ~$194k in H1 2025 revenue, mainly from wellness pilot programs.
View narrative
US$2.21
FV
24.9% overvalued
intrinsic discount
119.00%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
1
users have commented on this narrative
21
users have followed this narrative
Updated
narrative
Microsoft
PI
PicaCoder
Community Contributor
After the AI Party: A Sobering Look at Microsoft's Future
The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.
View narrative
US$500.00
FV
0.8% overvalued
intrinsic discount
6.75%
Revenue growth p.a.
Set Fair Value
19
users have liked this narrative
9
users have commented on this narrative
24
users have followed this narrative
10 days ago
author updated this narrative
Amazon.com
ZW
Zwfis
Community Contributor
Amazon's Future Rises as Stock Price Falls: A Long-Term Investment Vision
Amazon is a stock I am very interested in right now especially with the recent price drops that it has been experiencing since its 2Q25 results. A summary of Amazon as stated by Fiscal.ai: "Amazon.com, Inc.
View narrative
US$234.75
FV
5.5% undervalued
intrinsic discount
13.60%
Revenue growth p.a.
Set Fair Value
18
users have liked this narrative
7
users have commented on this narrative
22
users have followed this narrative
New
narrative
Verve Group
TI
TibiT
Community Contributor
Verve Group: A Tale of Three Futures
Verve Group stands at a critical juncture. After a history of explosive growth, the company has been hit by significant operational headwinds, primarily the difficult and costly migration to a unified technology platform and unfavorable currency exchange rates.
View narrative
€4.02
FV
45.5% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
15
users have followed this narrative
Updated
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Rani Therapeutics Holdings
AN
AnalystHighTarget
Consensus Narrative from 4 Analysts
Needle-Free Oral Biologics Will Serve Aging Global Demand
Key Takeaways Rani's oral therapy platform offers a significant adoption advantage and margin potential due to its non-invasive delivery and superior performance versus injections. Advancements in manufacturing and partnerships position the company for strong long-term growth while reducing reliance on dilutive financing.
View narrative
US$9.00
FV
93.9% undervalued
intrinsic discount
283.36%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Mersana Therapeutics
AN
AnalystHighTarget
Consensus Narrative from 7 Analysts
Precision Medicine And Global Aging Will Open Opportunities
Key Takeaways Emi-Le's broader therapeutic potential, enhanced dosing strategies, and demographic trends position Mersana for outsized growth and margin expansion in breast cancer markets. Strategic collaborations and proprietary ADC platforms diversify revenue, reduce cash burn, and support long-term growth in precision medicine.
View narrative
US$50.00
FV
83.8% undervalued
intrinsic discount
-7.37%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
EDAP TMS
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
Rising Health Spending And Aging Populations Will Boost HIFU Utilization
Key Takeaways Focal One's innovative, minimally invasive platform and AI integration position EDAP as a leader in women's health and technology-driven treatments, broadening its global market reach. Expanding clinical evidence, hospital partnerships, and new treatment indications are poised to drive rapid adoption, high-margin recurring revenues, and sustainable long-term growth.
View narrative
US$14.00
FV
90.4% undervalued
intrinsic discount
13.59%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Agenus
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
Precision Medicine And Global Aging Will Revolutionize Cancer Care
Key Takeaways Multiple transformative financing options and imminent investments could rapidly strengthen balance sheets and accelerate R&D, removing near-term funding concerns. Promising immunotherapy data, strong leadership, and strategic flexibility position the company for rapid market expansion, multi-indication approvals, and potential acquisition interest.
View narrative
US$23.00
FV
80.1% undervalued
intrinsic discount
12.18%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Sportsman's Warehouse Holdings
AN
AnalystHighTarget
Consensus Narrative from 5 Analysts
Sun Belt Trends And Digital Adoption Will Unlock Outdoor Opportunities
Key Takeaways Strategic focus on hunting, fishing, and exclusive brands, combined with digital growth and localized inventory, is driving industry-beating growth and improved profitability. Strong presence in high-growth regions and omnichannel initiatives are expanding market share, boosting margins, and enhancing long-term store productivity.
View narrative
US$4.25
FV
35.8% undervalued
intrinsic discount
2.12%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Karyopharm Therapeutics
AN
AnalystHighTarget
Consensus Narrative from 6 Analysts
Global Secular Trends Will Drive Adoption Of Targeted Oncology Therapies
Key Takeaways Breakthrough clinical outcomes and wide physician interest could drive substantially higher adoption and long-term revenue growth than current expectations. Expansion into biomarker-driven and underserved oncology markets creates potential for major new revenue streams and attractiveness for strategic partnerships or acquisitions.
View narrative
US$66.25
FV
90.9% undervalued
intrinsic discount
34.62%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Village Farms International
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
International Demand Will Fuel Premium Cannabis And Greenhouse Expansion
Key Takeaways International and premium segment growth, combined with efficient cost leverage, positions the company for significant margin expansion and industry leadership. Strategic asset moves and partnerships support aggressive growth initiatives, with unique infrastructure providing fast access to emerging sustainable and cannabis markets.
View narrative
US$4.50
FV
36.0% undervalued
intrinsic discount
-4.58%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
OptimizeRx
AN
AnalystHighTarget
Consensus Narrative from 6 Analysts
Digital Health Adoption And AI Will Drive Secular Expansion
Key Takeaways Rapid scaling of high-margin subscription offerings and AI-driven tools is positioning the company for outsized, sustained profitability with expanding margins. Strong market embedment and financial discipline create flexibility for strategic acquisitions and innovation, supporting long-term growth above industry averages.
View narrative
US$27.00
FV
40.2% undervalued
intrinsic discount
12.16%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
GrowGeneration
AN
AnalystHighTarget
Consensus Narrative from 2 Analysts
Cannabis Legalization And Global E-Commerce Will Expand Cultivation Supply Markets
Key Takeaways Proprietary product growth and accelerated digital platform adoption could rapidly enhance profitability and outpace competitor performance. Strategic acquisitions and international expansion offer diversification, access to emerging markets, and potential for substantial long-term revenue gains.
View narrative
US$2.50
FV
34.4% undervalued
intrinsic discount
-3.27%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Value any company in seconds
Popular companies